Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma

NCT02703779 is registered in ClinicalTrials.gov with Siddhartha Ganguly as lead sponsor.

NCT NCT02703779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02703779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
Lead sponsor
Siddhartha Ganguly
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2016
Completion date
April 8, 2020
Enrollment
101 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma